Real-World Effectiveness of IL-5/5Ra Targeted Biologics in Severe Eosinophilic Asthma With Comorbid Bronchiectasis

被引：6

作者：

Bendien, Sarah A. ^{[1
,18
]}

Kroes, Johannes A. ^{[2
]}

van Hal, Lotte H. G. ^{[2
]}

Braunstahl, Gert-Jan ^{[3
]}

Broeders, Marielle E. A. C. ^{[4
]}

Oud, Karen T. M. ^{[5
]}

Patberg, Kornelis Wiebe ^{[6
]}

Smeenk, Frank W. J. M. ^{[7
]}

van Veen, Ilonka H. P. A. A. ^{[8
]}

Weersink, Els J. M. ^{[9
]}

Fieten, Karin B. ^{[10
,11
]}

Hashimoto, Simone ^{[9
]}

van Veen, Anneke ^{[12
]}

Sont, Jaap K. ^{[13
]}

van Huisstede, Astrid ^{[14
]}

van de Ven, Marjo J. T. ^{[15
]}

Langeveld, Bas ^{[16
]}

Zee, Anke-Hilse Maitland-van der ^{[9
]}

机构：

[1] HAGA Teaching Hosp, Dept Pulmonol, The Hague, Netherlands

[2] Med Ctr Leeuwarden, Dept Clin Pharm & Pharmacol, Leeuwarden, Netherlands

[3] Franciscus Gasthuis & Vlietland, Dept Pulm Med, Rotterdam, Netherlands

[4] Jeroen Bosch Hosp, Dept Geriatr Med, Shertogenbosch, Netherlands

[5] Ziekenhuis Gelderse Vallei, Dept Resp Med, Ede, Netherlands

[6] ISALA Clin, Dept Resp Med, Zwolle, Netherlands

[7] Catharina Hosp, Dept Resp Med, Eindhoven, Netherlands

[8] Med Spectrum Twente, Dept Resp Med, Enschede, Netherlands

[9] Amsterdam UMC locat Univ Amsterdam, Dept Pulm Med, Amsterdam, Netherlands

[10] Dutch Asthma Ctr Davos NAD, Davos, Switzerland

[11] Univ Zurich, Swiss Inst Allergy & Asthma Res, Davos, Switzerland

[12] Canisius Wilhelmina Ziekenhuis, Dept Resp Med, Nijmegen, Netherlands

[13] Leiden Univ Med Ctr, Dept Biomed Data Sci, Med Decis Making Sect, Leiden, Netherlands

[14] Noordwest Ziekenhuisgroep, Dept Pulmonol, Alkmaar, Netherlands

[15] Rijnstate Hosp Arnhem, Dept Pulmonol, Arnhem, Netherlands

[16] Deventer Ziekenhuis, Dept Pulmonol, Deventer, Netherlands

[17] Med Ctr Leeuwarden, Dept Pulmonol, Leeuwarden, Netherlands

[18] Haga Teaching Hosp, Dept Hematol, Els Borst-Eilersplein 275, NL-2545 AA The Hague, Netherlands

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE | 2023年 / 11卷 / 09期

关键词：

Severe asthma; Bronchiectasis; Biologic therapy; Oral corticosteroids; MEPOLIZUMAB; OMALIZUMAB; EFFICACY; CORTICOSTEROIDS; BENRALIZUMAB; MULTICENTER; THERAPY;

D O I：

10.1016/j.jaip.2023.05.041

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

BACKGROUND: Bronchiectasis is a common comorbidity in patients with asthma and is associated with increased disease severity. In patients with severe eosinophilic asthma, biologics targeting IL-5/5Ra have beneficial effects on oral corticosteroid (OCS) use and exacerbation frequency. However, how coexisting bronchiectasis affects the response to such treatments is unknown.OBJECTIVE: To evaluate the real-world effectiveness of anti-IL-5/5Ra therapy in patients with severe eosinophilic asthma and comorbid bronchiectasis on exacerbation frequency and daily maintenance and cumulative OCS dose.METHODS: This real-world study evaluated data from 97 adults with severe eosinophilic asthma and computed tomographyeconfirmed bronchiectasis from the Dutch Severe Asthma Registry, who initiated anti-IL5/5Ra biologics (mepolizumab, reslizumab, and benralizumab) and had follow-up data for 12 months or greater. The analysis was performed for the total population and subgroups with or without maintenance OCS use.RESULTS: Anti-IL-5/5Ra therapy significantly reduced exacerbation frequency in patients with maintenance OCS use as well as in those without it. In the year before biologic initiation, 74.5% of all patients had two or more exacerbations, which decreased to 22.1% in the follow-up year (P < .001). The proportion of patients on maintenance OCS decreased from 47% to 30% (P < .001), and in the OCS-dependent patients (n [ 45) maintenance OCS dose decreased from median (interquartile range) of 10.0 mg/d (5-15 mg/d) to 2.5 mg/d (0-5 mg/d) after 1 year (P < .001).CONCLUSIONS: This real-world study shows that anti-IL-5/ 5Ra therapy reduces exacerbation frequency and daily maintenance as well as the cumulative OCS dose in patients with severe eosinophilic asthma and comorbid bronchiectasis. Although it is an exclusion criterion in phase 3 trials, comorbid bronchiectasis should not preclude anti-IL-5/5Ra therapy in patients with severe eosinophilic asthma. (c) 2023 American Academy of Allergy, Asthma & Immunology (J Allergy Clin Immunol Pract 2023;11:2724-31)

引用

页码：2724 / +

页数：10

共 50 条

[1] Real-world effectiveness of anti-IL-5/5R therapy in severe eosinophilic asthma with comorbid bronchiectasis
van Nederveen-Bendien, S. A.
Kroes, H.
Maitland-Van Der Zee, A.
Ten Brinke, A.
EUROPEAN RESPIRATORY JOURNAL, 2022, 60
[2] Real-World Effectiveness of Anti IL-5/IL-5R Therapies in Severe Asthma with Fungal Sensitisation
Dhariwal, J.
Kavanagh, J.
Roxas, C.
d'Ancona, G.
Green, L.
Thomson, L.
Fernandes, M.
Payne, V.
Kent, B. D.
Nanzer, A.
Jackson, D. J.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
[3] Anti-IL-5/5Ra biologics improve work productivity and activity in severe asthma.
Kuiper-Van der Valk, Hanna
Hekking, Pieter-Paul
EUROPEAN RESPIRATORY JOURNAL, 2023, 62
[4] Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma
Menigoz, C.
Dirou, S.
Chambellan, A.
Hassoun, D.
Moui, A.
Magnan, A.
Blanc, F. X.
JOURNAL OF ASTHMA, 2023, 60 (06) : 1162 - 1170
[5] Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma
Kavanagh, Joanne E.
Hearn, Andrew P.
Dhariwal, Jaideep
d'Ancona, Grainne
Douiri, Abdel
Roxas, Cris
Fernandes, Mariana
Green, Linda
Thomson, Louise
Nanzer, Alexandra M.
Kent, Brian D.
Jackson, David J.
CHEST, 2021, 159 (02) : 496 - 506
[6] A Real World, Single Center Experience of Treatment of Severe Eosinophilic Asthma with IL-5 Antagonists; Mepolizumab and Reslizumab
Mylvaganam, R.
Rogers, L.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
[7] Real-world effectiveness of reslizumab for severe eosinophilic asthma (SEA)
Subramaniam, Abirami
Mulligan, Emma
Lane, Stephen
EUROPEAN RESPIRATORY JOURNAL, 2019, 54
[8] Real-World Response To Anti-Eosinophil Biologics For Severe Eosinophilic Asthma
Surjancev, Ivana
Viswanathan, Ravi
Denlinger, Loren
Mathur, Sameer
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB18 - AB18
[9] THE COST-EFFECTIVENESS OF IL-5 INHIBITORS FOR PERSONS WITH EOSINOPHILIC ASTHMA
Jimenez, J.
Malone, D.
VALUE IN HEALTH, 2019, 22 : S354 - S354
[10] Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma
Bagnasco, Diego
Ferrando, Matteo
Varricchi, Gilda
Puggioni, Francesca
Passalacqua, Giovanni
Canonica, Giorgio Walter
FRONTIERS IN MEDICINE, 2017, 4

← 1 2 3 4 5 →